Sylentis Concludes Phase Ia Study of Glaucoma Drug

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.